Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of fluoropyrimidine-based chemotherapy plus cetuximab versus bevacizumab in KRAS wild-type metastatic colorectal cancer after bevacizumab first-line progression
2009-012942-22Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Fluoropyrimidine-based chemotherapy + cetuximab with Fluoropyrimidine-based chemotherapy + bevacizumab (2 arms). Primary endpoint: 4-month progression-free survival. Started Jul 2010; status: completed.
02
Drugs
cetuximabbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-012942-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012942-22.